What was AbbVie's revenue in Q4 2025?

AbbVie reported Q4 2025 revenue of $14.5 billion, up slightly from $14.3 billion in the same quarter last year.

Did AbbVie's earnings beat analyst expectations?

No, AbbVie's earnings missed estimates. Revenue was $14.5B vs. $14.8B expected, and EPS was $2.45 vs. $2.50 expected.

What is AbbVie's guidance for fiscal 2026?

AbbVie expects FY2026 revenue of $58-60 billion and EPS of $10.20-10.60, in line with analyst estimates.

How did AbbVie's stock react to the earnings?

AbbVie's stock fell 2% in after-hours trading following the earnings miss.

AbbVie Q4 2025 Earnings Miss Estimates; Stock Dips 2%

AbbVie reported Q4 2025 revenue of $14.5B and EPS of $2.45, missing analyst estimates of $14.8B and $2.50. The stock declined 2% in after-hours trading.

AbbVie Inc. (NYSE: ABBV) reported its fourth-quarter 2025 earnings, with revenue of $14.5 billion and earnings per share (EPS) of $2.45, both falling short of analyst expectations of $14.8 billion and $2.50, respectively. The stock dropped approximately 2% in after-hours trading following the announcement.

Key Financial Results

Metric	Q4 2025	Q4 2024	Change
Revenue	$14.5B	$14.3B	+1.4%
Net Income	$4.3B	$4.1B	+4.9%
EPS	$2.45	$2.35	+4.3%

Highlights from the Report

The company attributed the modest revenue growth to higher sales of Skyrizi and Rinvoq, which partially offset the decline in Humira sales due to biosimilar competition. AbbVie also highlighted continued investment in its pipeline.

Forward Guidance

For fiscal year 2026, AbbVie expects revenue between $58 billion and $60 billion, and EPS between $10.20 and $10.60, in line with analyst consensus of $59.5 billion and $10.40.

Stock Impact

AbbVie shares fell 2% in after-hours trading but remain up about 12% year-to-date. The stock has shown relative resilience despite concerns over Humira's patent expiration.

What This Means for Investors

AbbVie's results came in slightly below expectations, but the steady guidance may reassure investors. The focus now is on the company's ability to offset Humira's decline with new drugs. Investors should monitor pipeline developments and biosimilar competition.